Literature DB >> 17939062

Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC).

Johanne Geary1, Peter Sasieni, Richard Houlston, Louise Izatt, Ros Eeles, Stewart J Payne, Samantha Fisher, Shirley V Hodgson.   

Abstract

The family histories of 130 individuals with documented hereditary non-polyposis colorectal cancer (HNPCC) (caused by mutations in mismatch-repair (MMR) genes MSH2 (n = 64), MLH1 (n = 62) or MSH6 (n = 4)) were obtained, and incidence of cancers in those families was compared to that in the general population. There were a total of 982 cancers in 723 individuals. Colorectal cancer (CRC) was the commonest type (64% and 55% in individuals from families with germline MLH1 and MSH2 mutations respectively). Median age at diagnosis of first CRC in MSH6 mutation families was 59 years compared to 45 years in both MLH1 and MSH2 mutation families. The relative risk (RR) of endometrial cancer was 55 in MSH2 mutation families, compared with 27 in MLH1 mutation families, and 37 in MSH6 mutation families; median age at diagnosis 49 years. Even within MSH2 families, endometrial cancer tended to cluster, with 28 of the 58 cases coming from families with three or more cases (P < 0.001). Absolute risk of endometrial cancer in MLH1 families was still greater than any other cancer (other than CRC). 5% of cancers in both MLH1 and MSH2 mutation families were gastric (RR = 12); 53% of these were diagnosed before 50 years. Seven cases of small intestinal cancer occurred in MSH2 and MLH1 mutation families (RR = 26). There were 13 cases of cancer of the ureter; all were in MSH2 families. These cancers tended to cluster within families (P < 0.001); three of seven families with urothelial cancer had such cases in two or more individuals; two others had kidney cancer. Nineteen of 27 ovarian cancers (70%) were in MSH2 mutation families and 70% of these were diagnosed before age 50 years. There were 9 cases of sebaceous skin cancer, 3 in two MLH1 and 6 in four MSH2 mutation families. Of 22 pancreatic cancers, 14 were known to be diagnosed before 60 years. Breast cancer RR was 1.7 overall. The type of mutation (truncating or other type, and site of mutation) showed no obvious correlation with the presence or absence of extra-colonic cancers in families.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17939062     DOI: 10.1007/s10689-007-9164-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  26 in total

1.  Disease expression in Swiss hereditary non-polyposis colorectal cancer (HNPCC) kindreds.

Authors:  K Heinimann; H Müller; W Weber; R J Scott
Journal:  Int J Cancer       Date:  1997-06-20       Impact factor: 7.396

2.  A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome.

Authors:  E Mangold; C Pagenstecher; M Leister; M Mathiak; A Rütten; W Friedl; P Propping; T Ruzicka; R Kruse
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

3.  Clinical presentation correlates with the type of mismatch repair gene involved in hereditary nonpolyposis colon cancer.

Authors:  Prathap Bandipalliam; Judy Garber; Richard D Kolodner; Sapna Syngal
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

Review 4.  The tumor spectrum in the Lynch syndrome.

Authors:  Patrice Watson; Bronson Riley
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.

Authors:  Jens Plaschke; Christoph Engel; Stefan Krüger; Elke Holinski-Feder; Constanze Pagenstecher; Elisabeth Mangold; Gabriela Moeslein; Karsten Schulmann; Johannes Gebert; Magnus von Knebel Doeberitz; Josef Rüschoff; Markus Loeffler; Hans K Schackert
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

Review 6.  Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review.

Authors:  H T Lynch; T C Smyrk; P Watson; S J Lanspa; J F Lynch; P M Lynch; R J Cavalieri; C R Boland
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

7.  Familial transitional cell carcinoma and the Lynch syndrome II.

Authors:  J E Greenland; P M Weston; D M Wallace
Journal:  Br J Urol       Date:  1993-08

8.  The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands.

Authors:  H F Vasen; G J Offerhaus; F C den Hartog Jager; F H Menko; F M Nagengast; G Griffioen; R B van Hogezand; A P Heintz
Journal:  Int J Cancer       Date:  1990-07-15       Impact factor: 7.396

Review 9.  The Lynch syndromes.

Authors:  H T Lynch; J F Lynch
Journal:  Curr Opin Oncol       Date:  1993-07       Impact factor: 3.645

10.  Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.

Authors:  Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

View more
  59 in total

1.  Genetic susceptibility to pancreatic cancer.

Authors:  Alison P Klein
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  Genetic predisposition to pancreatic cancer.

Authors:  Paola Ghiorzo
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Inherited pancreatic cancer.

Authors:  Fei Chen; Nicholas J Roberts; Alison P Klein
Journal:  Chin Clin Oncol       Date:  2017-12

4.  [Standards for diagnostics and therapy of gastric cancer].

Authors:  N Schulte; M Ebert
Journal:  Internist (Berl)       Date:  2014-08       Impact factor: 0.743

Review 5.  Screening and early detection of pancreatic cancer in high risk population.

Authors:  Ming-Chu Chang; Jau-Min Wong; Yu-Ting Chang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

6.  Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry.

Authors:  Michael D Walsh; Daniel D Buchanan; Margaret C Cummings; Sally-Ann Pearson; Sven T Arnold; Mark Clendenning; Rhiannon Walters; Diane M McKeone; Amanda B Spurdle; John L Hopper; Mark A Jenkins; Kerry D Phillips; Graeme K Suthers; Jill George; Jack Goldblatt; Amanda Muir; Kathy Tucker; Elise Pelzer; Michael R Gattas; Sonja Woodall; Susan Parry; Finlay A Macrae; Robert W Haile; John A Baron; John D Potter; Loic Le Marchand; Bharati Bapat; Stephen N Thibodeau; Noralane M Lindor; Michael A McGuckin; Joanne P Young
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

7.  Genotype-phenotype correlation in MMR mutation-positive families with Lynch syndrome.

Authors:  Lucía Pérez-Cabornero; Mar Infante; Eladio Velasco; Enrique Lastra; Cristina Miner; Mercedes Durán
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

8.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

Review 9.  Early diagnosis of pancreatic cancer: challenges and new developments.

Authors:  Sukhwinder Kaur; Michael J Baine; Maneesh Jain; Aaron R Sasson; Surinder K Batra
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

Review 10.  Surveillance for urinary tract cancer in Lynch syndrome.

Authors:  Inge Thomsen Bernstein; Torben Myrhøj
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.